Literature DB >> 989419

[Concentration of cardiac glycosides in the heart and brain (author's transl)].

H Flasch, N Heinz.   

Abstract

In cats the concentration of cardio-active glycosides in the heart and brain were investigated with trititum-labelled substances. Steady-state conditions were achieved by repeated i.v. injections of ouabain, digoxin, beta-methyldigoxin, digitoxin, and oleandrin over 5 days. 5 h after the last application glycoside concentrations were measured in plasma, urine, heart, cerebrum and cerebellum. Furthermore the metabolic pattern in these compartments was determined. 1. The glycoside concentration in the heart per g wet weight ranges only from 0.93 (oleandrin) to 1.88% (ouabain) of the daily administered dose per kg. 2. The concentrations in the brain show much higher differences between the diverse glycosides: ouabain with a concentration of 0.02%/g wet weight in the cerebrum shows the lowest and oleandrin with 1.60% the highest value. 3. By calculating the mean relative weights for the hearts (3.9 g/kg) and the brains (11.1 g/kg) 3.7% of the daily administered ouabain activity were found in the whole heart and only 0.18% in the whole brain. In contrast to these data the content of heart and brain after giving the more lipophilic oleandrin was 3.6% and 17.7% (!), respectively. 4. Under steady-state conditions the glycosides ouabain, digoxin, beta-methyldigoxin and digitoxin in heart and brain are mainly unchanged whereas oleandrin is transformed at a higher rate to polar metabolites.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 989419

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  6 in total

1.  Distribution of cardiac glycosides in heart and brain of dogs and their affinity to the (Na+ + K+)-ATPase.

Authors:  J Kuhlmann; E Erdmann; N Rietbrock
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1979-05       Impact factor: 3.000

2.  Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdr 1a P-glycoprotein.

Authors:  U Mayer; E Wagenaar; J H Beijnen; J W Smit; D K Meijer; J van Asperen; P Borst; A H Schinkel
Journal:  Br J Pharmacol       Date:  1996-11       Impact factor: 8.739

3.  beta-Methyl-digoxin. VIII. Relation of cerebral side-effects in cats to concentrations in the plasma and in the brain.

Authors:  K Dietmann; E Hrstka; K Koch; W Schaumann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1978-03       Impact factor: 3.000

4.  Cardiac glycoside-mediated turnover of Na, K-ATPases as a rational approach to reducing cell surface levels of the cellular prion protein.

Authors:  Mohadeseh Mehrabian; Xinzhu Wang; Shehab Eid; Bei Qi Yan; Mark Grinberg; Murdock Siegner; Christopher Sackmann; Muhammad Sulman; Wenda Zhao; Declan Williams; Gerold Schmitt-Ulms
Journal:  PLoS One       Date:  2022-07-01       Impact factor: 3.752

5.  Pharmacokinetics of dihydrodigitoxin in the cat. A comparison with digitoxin.

Authors:  H Flasch; N Heniz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1979-12       Impact factor: 3.000

6.  Comparison of the pharmacokinetics of digoxin and dihydrodigoxin in cats in single-dose studies.

Authors:  N Heinz; H Flasch
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1978-06       Impact factor: 3.000

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.